Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250708 | 1.00 | ESR1 (0.46) | ESR1ESR2FOLH1MDM4MDM2 | |
| SCHEMBL12250719 | 1.00 | ESR1 (0.46) | ESR1ESR2FOLH1MDM4MDM2 | |
| SCHEMBL10061085 | 0.87 | ATM (0.43) | ACEMMEACE2KMT2ANPSR1 | |
| SCHEMBL12250692 | 0.87 | ATM (0.43) | ACEMMEACE2KMT2ANPSR1 | |
| SCHEMBL26417010 | 0.87 | ATM (0.43) | ACEMMEACE2KMT2ANPSR1 | |
| SCHEMBL23065772 | 0.86 | HDAC1 (0.45) | MMECTSSCTSKKMT2ASMN1; SMN2 | |
| SCHEMBL12250727 | 0.86 | NOS2 (0.45) | ACECTSSCTSK | |
| SCHEMBL23974737 | 0.86 | LOXL2 (0.40) | ACEMMEACE2GRIA1MAPT | |
| SCHEMBL14011032 | 0.86 | NOS2 (0.45) | ACECTSSCTSK | |
| SCHEMBL14347563 | 0.86 | NOS2 (0.45) | ACECTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365963-A1 | METHODS FOR TREATING NEUROLOGICAL DISEASE | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11407741-B2 | Compounds and their use as selective inhibitors of caspase-2 | Universite De Paris (FR) | 2022-08-09 | — | — | US | disclosed |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | SANTOLECAN PHARMACEUTICALS LLC | 2021-07-29 | — | — | US | disclosed |
| US-20200317647-A1 | NOVEL COMPOUNDS AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | UNIVERSITÉ PARIS CITÉ (FR) | 2020-10-08 | — | — | US | disclosed |
| US-9981008-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2018-05-29 | — | — | US | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| US-9593156-B2 | Insulin analog dimers | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-9573987-B2 | CTP-based insulin analogs for treatment of diabetes | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160340400-A1 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | UNIV INDIANA RES & TECH CORP (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-11-10 | — | — | US | disclosed |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-09-05 | — | — | US | disclosed |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2013-08-08 | — | — | US | disclosed |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2013-08-01 | — | — | US | disclosed |
| US-20130123171-A1 | AMIDE-BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORA (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120021982-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2012-01-26 | — | — | US | disclosed |
| WO-2011156003-A2 | PEPTOID AND SYNTHETIC OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20110257076-A1 | AMIDE BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2011-10-20 | — | — | US | disclosed |
| US-20110245164-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090281032-A1 | Modified CCK peptides | UNIVERSITY OF ULSTER (GB) | 2009-11-12 | — | — | US | disclosed |
| US-7312211-B2 | Pryanone compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123171-A1 | AMIDE-BASED INSULIN PRODRUGS | IAPP, IDE, DNPEP | ESR1 1236/4885ESR2 2536/4885FOLH1 530/4885 |
| US-20110257076-A1 | AMIDE BASED INSULIN PRODRUGS | IAPP, IDE, DNPEP | ESR1 1145/4885ESR2 2331/4885FOLH1 560/4885 |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | ESR1 2948/4885ESR2 1615/4885FOLH1 2075/4885 |
| US-20120021982-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION | APOB, FABP3, TNNT2 | ESR1 4022/4885ESR2 2453/4885FOLH1 2226/4885 |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | DDOST, UGT2B17, UGT1A7 | ESR1 4145/4885ESR2 3429/4885FOLH1 144/4885 |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | ESR1 3767/4885ESR2 2232/4885FOLH1 1653/4885 |
| US-20230365963-A1 | METHODS FOR TREATING NEUROLOGICAL DISEASE | HTT, ATP6V1B2, SYNCRIP | ESR1 1937/4885ESR2 2052/4885FOLH1 1979/4885 |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | ESR1 124/4885ESR2 430/4885FOLH1 977/4885 |
| US-20200317647-A1 | NOVEL COMPOUNDS AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | CASP2, CASP1, CASP5 | ESR1 2792/4885ESR2 2250/4885FOLH1 272/4885 |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | ESR1 2948/4885ESR2 1615/4885FOLH1 2075/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | ESR1 2448/4885ESR2 1344/4885FOLH1 138/4885 |
| US-20090281032-A1 | Modified CCK peptides | CCKAR, PTMS, VIP | ESR1 3450/4885ESR2 2661/4885FOLH1 488/4885 |
| US-11407741-B2 | Compounds and their use as selective inhibitors of caspase-2 | CASP2, CASP1, CASP3 | ESR1 2752/4885ESR2 2380/4885FOLH1 249/4885 |
| US-20110245164-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, INSR, IGFBP1 | ESR1 1484/4885ESR2 1687/4885FOLH1 1108/4885 |
| US-20160340400-A1 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | ESR1 131/4885ESR2 434/4885FOLH1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.